The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

Annals of Allergy, Asthma and Immunology

Volumn 92, Issue 1, 2004, Pages 3-4

  Osborne, Molly ^a   Deffebach, Mark ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ASTHMA; DISEASE CONTROL; DISEASE COURSE; DRUG RESEARCH; EDITORIAL; HEALTH CARE UTILIZATION; HUMAN; IMMUNOTHERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL;

EID: 1642536607     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61702-4     Document Type: Editorial

References (7)

1. Apter AJ. Clinical advances in adult asthma. J Allergy Clin Immunol. 2003;111:S780-S784.
2. Stafford RS, Ma J, Finkelstein SN, et al. National trends in asthma visits and asthma pharmacotherapy, 1978-2002. J Allergy Clin Immunol. 2003;111:729-735.
3. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis, I: assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
4. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92:32-39.
5. Kennedy S, Stone A, Rachelefsky G. Factors associated with emergency department use in asthma: acute care interventions improving chronic disease outcomes. Ann Allergy Asthma Immunol. 2003;90:45-50.
6. Osborne ML, Vollmer WM, Pedula KL, et al. Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest. 1999;115:85-91.
7. Lazaar AL. Technology evaluation: omalizumab, Genentech/Novartis/Tanox. Curr Opin Mol Ther. 2003;5:81-89.